CEL-SCI (AMEX:CVM) Stock

CEL-SCI

CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.

CEL-SCI Corp

Morgan Stanley ETF Trust Calvert US Mid-Cap Core Responsible Index ETF

Sila Realty Trust Inc Ordinary Shares - Class A

Sila Realty Trust Inc Ordinary Shares - Class T

<h3>Gainers</h3>
<ul>
<li>Vigil Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIGL#NASDAQ">VIGL</a>) shares moved upwards by 241.8% to $7.89 during Thursday's regular session. The company's market cap stands at $368.4 million. </li>
<li>Instil Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIL#NASDAQ">TIL</a>) stock increased by 48.15% to $24.03. The market value of their outstanding shares is at $157.6 million. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock rose 32.85% to $1.86. The company's market cap stands at $5.3 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) stock rose 27.77% to $3.91. The market value of their outstanding shares is at $3.9 million. </li>
<li>Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) shares increased by 22.86% to $9.94. The company's market cap stands at $121.4 million. </li>
<li>Ventyx Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTYX#NASDAQ">VTYX</a>) stock rose 21.24% to $1.85. The market value of their outstanding shares is at $132.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) stock fell 45.5% to $2.46 during Thursday's regular session. The company's market cap stands at $7.4 million. </li>
<li>Basel Medical Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) shares fell 31.29% to $1.28. The market value of their outstanding shares is at $24.1 million. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) stock fell 30.47% to $0.21. The company's market cap stands at $2.3 million. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock declined by 21.32% to $0.0. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) stock fell 21.04% to $0.3. The market value of their outstanding shares is at $2.3 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares declined by 15.01% to $0.01. As per the press release, Q1 earnings came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

APVO

BMGL

EYEN

HCTI

PLRZ

VIGL

VTAK

VTYX

Longevity Health Holdings, Inc. - Common Stock

XAGE

12 Health Care Stocks Moving In Thursday's Intraday Session

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 0.2% on Thursday.
The Dow traded up 0.17% to 41,932.94 while the NASDAQ rose 0.66% to 18,997.89. The S&amp;P 500 also rose, gaining, 0.20% to 5,856.28.
Check This Out: <a href="https://www.benzinga.com/25/05/45563601/how-to-earn-500-a-month-from-intuit-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Intuit Stock Ahead Of Q3 Earnings</a>
Leading and Lagging Sectors Communication services shares rose by 1.2% on Thursday.
In trading on Thursday, utilities stocks dipped by 1.9%.
Top Headline
U.S. initial jobless claims fell by 2,000 from the previous week to 227,000 in the week ending May 17, compared to market estimates of 230,000.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Vigil Neuroscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIGL#NASDAQ">VIGL</a>) shares shot up 242% to $7.91 after announcing Sanofi will acquire the company for approximately $600 million.</li>
<li>Shares of Navitas Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) got a boost, surging 130% to $4.3988 after NVIDIA selected the company to collaborate on 800 V HVDC architecture.</li>
<li>Advance Auto Parts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) shares were also up, gaining 46% to $45.61 following better-than-expected first-quarter financial results.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>CEL-SCI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) shares dropped 45% to $2.4887 following announcements for a $5 million public offering.</li>
<li>Shares of Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) were down 39% to $6.49. BMO Capital analyst Ameet Thakkar downgraded Sunrun from Market Perform to Underperform and lowered the price target from $9 to $4.</li>
<li>Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) was down, falling 19% to $38.25. Shares of solar companies tumbled as investors digested the consequences of President Donald Trump&#8217;s sweeping budget and tax package dubbed "One Big, Beautiful Bill.&#8221;</li>
</ul>
Commodities In commodity news, oil traded down 0.9% to $61.02 while gold traded down 0.3% at $3,302.90.
Silver traded down 1.5% to $33.13 on Thursday, while copper fell 0.3% to $4.660.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.89%, while Spain's IBEX 35 Index fell 0.56%. London's FTSE 100 dipped 0.85%, Germany's DAX 40 declined 0.69% and France's CAC 40 fell 0.95% during the session.
Asia Pacific Markets
Asian markets closed lower on Thursday, with Japan's Nikkei falling 0.84%, Hong Kong's Hang Seng Index dipping 1.19%, China's Shanghai Composite Index falling 0.22% and India's BSE Sensex declining 0.79%.
Economics
<ul class="wp-block-list">
<li>U.S. existing home sales fell 0.5% month-over-month to an annual rate of 4.00 million in April, recording the lowest level in six months.</li>
<li>The S&amp;P Global services PMI climbed to 52.3 in May compared to 50.8 in the previous month.</li>
<li>The S&amp;P Global manufacturing PMI rose to 52.3 in May from 50.2 in April.</li>
<li>The Chicago Fed National Activity Index dipped to -0.25 in April compared to a revised reading of +0.03 in March.</li>
<li>U.S. initial jobless claims fell by 2,000 from the previous week to 227,000 in the week ending May 17, compared to market estimates of 230,000.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45564349/accenture-to-rally-more-than-24-here-are-10-top-analyst-forecasts-for-thursday">Accenture To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Thursday</a> </li>
</ul>
Photo via Shutterstock

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ENPH

NVTS

Dow Moves Higher; US Initial Jobless Claims Fall

U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining more than 100 points on Thursday.
Following the market opening Thursday, the Dow traded up 0.01% to 41,866.30 while the NASDAQ rose 0.74% to 19,011.97. The S&amp;P 500 also rose, gaining, 0.20% to 5,856.20.
Check This Out: <a href="https://www.benzinga.com/25/05/45563601/how-to-earn-500-a-month-from-intuit-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Intuit Stock Ahead Of Q3 Earnings</a>
Leading and Lagging Sectors Communication services shares rose by 1.7% on Thursday.
In trading on Thursday, utilities stocks dipped by 1.8%.
Top Headline
BJ's Wholesale Club Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>) posted better-than-expected earnings for its first quarter on Thursday.
The company registered adjusted earnings per share of $1.14, beating the analyst consensus estimate of 92 cents. Quarterly revenues of $5.15 billion (+4.7% year over year) missed the Street view of $5.20 billion.
BJ's Wholesale Club has reaffirmed its full-year 2025 adjusted earnings guidance of $4.10 to $4.30 per share, compared with the $4.24 estimate.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Vigil Neuroscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIGL#NASDAQ">VIGL</a>) shares shot up 243% to $7.91 after announcing Sanofi will acquire the company for approximately $600 million.</li>
<li>Shares of Navitas Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) got a boost, surging 128% to $4.3335 after NVIDIA selected the company to collaborate on 800 V HVDC architecture.</li>
<li>Advance Auto Parts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) shares were also up, gaining 44% to $45.14 following better-than-expected first-quarter financial results.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>CEL-SCI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) shares dropped 46% to $2.4309 following announcements for a $5 million public offering.</li>
<li>Shares of Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) were down 40% to $6.44. BMO Capital analyst Ameet Thakkar downgraded Sunrun from Market Perform to Underperform and lowered the price target from $9 to $4.</li>
<li>Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) was down, falling 16% to $39.85.</li>
</ul>
Commodities In commodity news, oil traded down 1.6% to $60.57 while gold traded down 0.6% at $3,294.10.
Silver traded down 1.8% to $33.04 on Thursday, while copper fell 0.7% to $4.6410.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 1.1%, while Spain's IBEX 35 Index fell 0.7%. London's FTSE 100 dipped 1%, Germany's DAX 40 declined 0.9% and France's CAC 40 fell 1.1% during the session.
Asia Pacific Markets
Asian markets closed lower on Thursday, with Japan's Nikkei falling 0.84%, Hong Kong's Hang Seng Index dipping 1.19%, China's Shanghai Composite Index falling 0.22% and India's BSE Sensex declining 0.79%.
Economics
<ul class="wp-block-list">
<li>U.S. existing home sales fell 0.5% month-over-month to an annual rate of 4.00 million in April, recording the lowest level in six months.</li>
<li>The S&amp;P Global services PMI climbed to 52.3 in May compared to 50.8 in the previous month.</li>
<li>The S&amp;P Global manufacturing PMI rose to 52.3 in May from 50.2 in April.</li>
<li>The Chicago Fed National Activity Index dipped to -0.25 in April compared to a revised reading of +0.03 in March.</li>
<li>U.S. initial jobless claims fell by 2,000 from the previous week to 227,000 in the week ending May 17, compared to market estimates of 230,000.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45564349/accenture-to-rally-more-than-24-here-are-10-top-analyst-forecasts-for-thursday">Accenture To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Thursday</a> </li>
</ul>
Photo via Shutterstock

Nasdaq Gains Over 100 Points; BJ's Wholesale Earnings Top Views

WIIM

CEL-SCI shares are trading lower following announcements for a $5 million public offering.

<h3>Gainers</h3>
<ul>
<li>Vigil Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIGL#NASDAQ">VIGL</a>) stock increased by 243.7% to $7.94 during Thursday's pre-market session. The market value of their outstanding shares is at $370.5 million. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) shares moved upwards by 62.41% to $4.97. The market value of their outstanding shares is at $4.9 million. </li>
<li>Ventyx Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTYX#NASDAQ">VTYX</a>) shares increased by 13.01% to $1.73. The market value of their outstanding shares is at $123.0 million. </li>
<li>Kindly MD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) shares rose 12.79% to $25.75. The company's market cap stands at $155.0 million. </li>
<li>HOOKIPA Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOK#NASDAQ">HOOK</a>) stock increased by 11.84% to $1.7. The market value of their outstanding shares is at $20.7 million. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock increased by 10.57% to $4.81. The market value of their outstanding shares is at $2.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) shares fell 47.5% to $2.37 during Thursday's pre-market session. The company's market cap stands at $7.1 million. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) stock fell 17.55% to $0.25. The company's market cap stands at $2.7 million. </li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares fell 8.8% to $52.9. The company's market cap stands at $11.8 billion. </li>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) shares decreased by 8.66% to $0.36. The company's market cap stands at $52.8 million. </li>
<li>MetaVia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTVA#NASDAQ">MTVA</a>) stock decreased by 7.49% to $0.81. The company's market cap stands at $15.8 million. </li>
<li>Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) stock decreased by 7.49% to $3.09. The market value of their outstanding shares is at $33.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BDSX

Hims & Hers Health, Inc. Class A Common Stock

HIMS

HOOK

HSDT

KDLY

LTRN

MTVA

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Shares of Urban Outfitters, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) rose sharply in today's pre-market following better-than-expected <a href="https://in.benzinga.com/markets/equities/25/05/45559366/urban-outfitters-navigates-tariff-headwinds-with-diversification-strategies-no-country-accounts-for-more-than-25-of-production">first-quarter financial results.</a>
Urban Outfitters reported quarterly earnings of $1.16 per share, which beat the analyst consensus estimate of 82 cents. Quarterly revenue clocked in at $1.33 billion, which beat the Street estimate of $1.28 billion.
Urban Outfitters shares jumped 18% to $70.32 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>Navitas Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) rose 172.2% to $5.20 in pre-market trading after NVIDIA selected the company to collaborate on 800 V HVDC architecture.</li>
<li>Longevity Health Holdings, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) surged 60.1% to $4.87 in pre-market trading after the company announced it will retain its Nasdaq listing to complete its merger with 20/20 Biolabs.</li>
<li>AtlasClear Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATCH#NYSE">ATCH</a>) jumped 23.2% to $0.2487 in pre-market trading after falling 11% on Wednesday.</li>
<li>Bit Origin Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTOG#NASDAQ">BTOG</a>) gained 20.9% to $0.1920 in pre-market trading after declining 9% on Wednesday.</li>
<li>Nine Energy Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NINE#NYSE">NINE</a>) surged 19.7% to $0.6057 in pre-market trading after falling 10% on Wednesday.</li>
<li>Kindly MD, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) gained 16.9% to $26.69 in pre-market trading. Nakamoto Holdings, Kindly MD, and Anchorage Digital disclosed a strategic partnership to advance the future of corporate Bitcoin adoption.</li>
<li>Lumen Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) climbed 14.6% to $4.37 in pre-market trading after the company announced the sale of its consumer fiber-to-the-home business to AT&amp;T for $5.75 billion in cash.</li>
<li>Pitney Bowes Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBI#NYSE">PBI</a>) gained 11.4% to $10.14 in pre-market trading after the company reported better-than-expected first-quarter adjusted EPS results.</li>
<li>Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) rose 10.3% to $197.52 in pre-market trading after the company posted better-than-expected earnings and sales results for the first quarter. The company also said it expects second-quarter product revenue in the range of $1.035 billion to $1.04 billion, up approximately 25% year-over-year. The company anticipates full-year product revenue of $4.33 billion, representing 25% year-over-year growth.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>CEL-SCI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) shares fell 43.7% to $2.54 in pre-market trading after the company reported the pricing of public offering.</li>
<li>Catheter Precision, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#NYSE">VTAK</a>) fell 18.8% to $0.2450 in pre-market trading. Catheter Precision filed for resale of up to 12.9 million shares of common stock by the selling stockholders.</li>
<li>Wheeler Real Estate Investment Trust, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>) fell 16.1% to $0.89 in today's pre-market trading after announcing a 1-for-7 reverse stock split.</li>
<li>Lottery.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRY#NASDAQ">LTRY</a>) shares dipped 15.2% to $1.51 in pre-market trading. Lottery.com shares jumped 135% on Wednesday after the company reported a year-over-year increase in first-quarter EPS results.</li>
<li>Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) shares tumbled 15.1% to $9.05 in pre-market trading after declining around 8% on Wednesday.</li>
<li>Digital Ally, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGLY#NASDAQ">DGLY</a>) fell 13.7% to $0.0259 in pre-market trading. Digital Ally shares fell around 17% on Wednesday after the company reported a year-over-year decrease in first-quarter sales results.</li>
<li>Vast Renewables Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) dipped 13.6% to $0.1450 in pre-market trading after tumbling 10% on Wednesday.</li>
<li>Upexi, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPXI#NASDAQ">UPXI</a>) declined 9.5% to $11.56 in pre-market trading after gaining over 29% on Wednesday.</li>
<li>Manchester United plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MANU#NYSE">MANU</a>) shares fell 6.9% to $13.54 in pre-market trading.</li>
<li>SolarEdge Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) fell 5.2% to $18.81 in pre-market trading. GLJ Research analyst Gordon Johnson, on Wednesday, maintained SolarEdge with a Sell and raised the price target from $3.9 to $6.9.</li>
</ul>
Now Read This:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/25/05/45540545/jim-cramer-recommends-not-buying-mosaic-doesnt-like-this-industrial-stock">Jim Cramer Recommends Not Buying Mosaic, Doesn&#8217;t Like This Industrial Stock</a> </li>
</ul>
Photo via Shutterstock

ATCH

BTOG

DGLY

LTRY

LUMN

MANU

NINE

SEDG

SNOW

UPXI

URBN

VSTE

WHLR

Why Urban Outfitters Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket

Reported Earlier, CEL-SCI Prices $5M Public Offering At $2.50/Share To Advance Multikine Cancer Immunotherapy Development

<h3>Gainers</h3>
<ul>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) shares moved upwards by 55.5% to $4.76 during Wednesday's after-market session. The market value of their outstanding shares is at $4.7 million. </li>
<li>SAB Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SABS#NASDAQ">SABS</a>) shares moved upwards by 15.94% to $2.0. The market value of their outstanding shares is at $18.5 million. </li>
<li>AEON Biopharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AEON#AMEX">AEON</a>) stock rose 9.3% to $0.53. The market value of their outstanding shares is at $6.0 million. </li>
<li>Lipella Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) shares rose 7.26% to $3.1. The company's market cap stands at $13.8 million. </li>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) stock moved upwards by 7.2% to $1.99. The market value of their outstanding shares is at $2.9 million. </li>
<li>Immutep (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMMP#NASDAQ">IMMP</a>) stock moved upwards by 6.7% to $2.07. The market value of their outstanding shares is at $301.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) shares decreased by 37.0% to $0.04 during Wednesday's after-market session. As per the news, the Q1 earnings report came out 4 days ago. </li>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) stock declined by 20.4% to $3.59. The company's market cap stands at $326.8 million. The company's, Q2 earnings came out 4 days ago. </li>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) shares decreased by 12.72% to $1.03. The market value of their outstanding shares is at $5.8 million. As per the news, the Q1 earnings report came out 4 days ago. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) stock fell 12.26% to $0.27. The company's market cap stands at $2.9 million. </li>
<li>BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) stock decreased by 7.02% to $0.36. The market value of their outstanding shares is at $21.0 million. </li>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) shares decreased by 6.76% to $0.37. The market value of their outstanding shares is at $53.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEON

BCAB

BCLI

BJDX

IMMP

LIPO

PTPI

SABS

12 Health Care Stocks Moving In Wednesday's After-Market Session

CEL-SCI shares are trading lower after the company announced a proposed public offering.

CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:<a href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>), a clinical stage cancer immunotherapy company,today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants ("Pre-Funded Warrants") in lieu thereof) in an underwritten public offering. All of the shares of common stock (and/or Pre-Funded Warrants) are being offered by the Company. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
The Company intends to use the net proceeds from this offering to fund the continued development of Multikine&#x2A;, for general corporate purposes, and working capital.
ThinkEquity is acting as sole book-running manager for the offering.

CEL-SCI Announces Proposed Public Offering; No Size Or Amount Disclosed

CEL-SCI Completes Breakthrough Medicine Designation Application For Multikine For Submission To Saudi Food And Drug Authority

<h3>Gainers</h3>
<ul>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) stock moved upwards by 39.5% to $0.38 during Tuesday's after-market session. The company's market cap stands at $55.3 million. </li>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) stock rose 26.37% to $0.16. The company's, Q1 earnings came out 3 days ago. </li>
<li>MetaVia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTVA#NASDAQ">MTVA</a>) stock rose 15.6% to $0.81. The market value of their outstanding shares is at $8.2 million. As per the press release, Q1 earnings came out 4 days ago. </li>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) stock rose 9.8% to $5.61. The market value of their outstanding shares is at $510.8 million. The company's, Q2 earnings came out 3 days ago. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock rose 7.23% to $0.44. The market value of their outstanding shares is at $12.1 million. </li>
<li>VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) stock increased by 6.7% to $0.52. The market value of their outstanding shares is at $53.9 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares fell 9.0% to $5.49 during Tuesday's after-market session. The market value of their outstanding shares is at $83.5 million. </li>
<li>HeartSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSCS#NASDAQ">HSCS</a>) shares declined by 6.46% to $4.2. The company's market cap stands at $4.5 million. </li>
<li>OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) stock fell 6.21% to $11.18. The company's market cap stands at $206.7 million. </li>
<li>HilleVax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLVX#NASDAQ">HLVX</a>) stock declined by 5.95% to $1.9. The company's market cap stands at $95.1 million. </li>
<li>Intensity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) shares decreased by 5.94% to $0.39. The company's market cap stands at $7.1 million. </li>
<li>Xtant Medical Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/XTNT#AMEX">XTNT</a>) stock decreased by 5.77% to $0.66. The market value of their outstanding shares is at $92.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HLVX

HSCS

INTS

ONMD

OPRX

VNRX

XTNT

12 Health Care Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) stock moved upwards by 2412.3% to $5.12 during Tuesday's regular session. The company's market cap stands at $466.1 million. The company's, Q2 earnings came out 3 days ago. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock increased by 42.47% to $1.61. The company's market cap stands at $4.5 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock moved upwards by 23.28% to $0.28. The company's market cap stands at $5.0 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares increased by 22.5% to $431.22. The market value of their outstanding shares is at $5.6 billion. </li>
<li>Quantum-Si (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) stock rose 18.79% to $1.68. The market value of their outstanding shares is at $307.3 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>TELA Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELA#NASDAQ">TELA</a>) shares increased by 17.2% to $1.35. The company's market cap stands at $53.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock fell 31.1% to $7.65 during Tuesday's regular session. The market value of their outstanding shares is at $4.5 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) shares decreased by 17.74% to $8.88. The company's market cap stands at $243.0 million. </li>
<li>Ekso Bionics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) shares fell 15.14% to $0.28. The company's market cap stands at $8.1 million. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares decreased by 13.64% to $0.01. </li>
<li>Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) shares declined by 12.62% to $7.38. The company's market cap stands at $629.6 million. </li>
<li>Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) shares declined by 11.85% to $5.25. The company's market cap stands at $285.3 million. The company's, Q1 earnings came out 4 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALMS

AVXL

BIAF

DBVT

EKSO

PTIX

TELA

12 Health Care Stocks Moving In Tuesday's Intraday Session

CEL-SCI Corporation (NYSE:<a href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) announced today that during its annual Shareholder's Meeting on May 19, 2025, a combination was authorized for its outstanding shares of common stock. On May 19, 2025, the Board of Directors approved a 1 for 30 combination of common stock. CEL-SCI expects the combination to be implemented on May 20, 2025. When the market opens on May 20, 2025, the common stock will trade under a new CUSIP number 150837 706, but the Company's ticker symbol, CVM, will remain unchanged.
When the combination of stock becomes effective, every 30 shares of common stock will be converted into 1 share of common stock. The combination of common stock will not eliminate any shareholders of record since any fractional share resulting from the combination of common stock will be rounded to the nearest whole share. The exercise price of all outstanding warrants and options, as well as the shares issuable upon the exercise of the outstanding warrants and options, will also be proportionately adjusted.

CEL-SCI Corp. Board Approves 1-For-30 Stock Combination, Effective May 20, 2025

CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) reported quarterly losses of $(0.08) per share. This is a 42.86 percent increase over losses of $(0.14) per share from the same period last year.

CEL-SCI Q2 EPS $(0.08) Up From $(0.14) YoY

<h3>Gainers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares rose 65.3% to $1.67 during Friday's after-market session. The market value of their outstanding shares is at $66.4 million. </li>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) stock moved upwards by 9.35% to $1.67. The market value of their outstanding shares is at $3.2 million. </li>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) shares rose 7.45% to $0.27. The market value of their outstanding shares is at $22.6 million. </li>
<li>BioCardia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) shares moved upwards by 7.08% to $2.87. The market value of their outstanding shares is at $13.1 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) stock moved upwards by 6.66% to $1.28. The company's market cap stands at $23.6 million. </li>
<li>LENZ Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LENZ#NASDAQ">LENZ</a>) stock moved upwards by 6.63% to $31.48. The market value of their outstanding shares is at $867.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) shares decreased by 24.2% to $0.39 during Friday's after-market session. The company's market cap stands at $9.0 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock declined by 15.75% to $0.63. The market value of their outstanding shares is at $7.2 million. </li>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) shares decreased by 12.09% to $1.6. The company's market cap stands at $21.2 million. </li>
<li>BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) stock declined by 10.86% to $3.04. The company's market cap stands at $11.3 million. </li>
<li>Palisade Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) shares fell 8.63% to $0.74. The market value of their outstanding shares is at $3.4 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) stock declined by 7.4% to $0.6. The company's market cap stands at $3.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BCDA

BIVI

BLRX

LENZ

PALI

PSTV

RNAZ

THAR

12 Health Care Stocks Moving In Friday's After-Market Session

Biotech

General

CEL-SCI Met With Saudi Food And Drug Authority, Says Is Preparing To Submit A Regulatory Filing For The Approval Of Multikine As A Neoadjuvant Treatment Of Newly Diagnosed Previously Untreated Locally Advanced Head And Neck Cancer

<h3>Gainers</h3>
<ul>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares moved upwards by 68.6% to $0.04 during Monday's regular session. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) stock rose 54.25% to $0.19. The market value of their outstanding shares is at $5.7 million. </li>
<li>Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) stock increased by 39.56% to $5.08. The company's market cap stands at $229.1 million. </li>
<li>Metsera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSR#NASDAQ">MTSR</a>) shares increased by 34.27% to $18.8. The market value of their outstanding shares is at $1.9 billion. </li>
<li>Wellgistics Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGRX#NASDAQ">WGRX</a>) stock increased by 31.14% to $3.79. The company's market cap stands at $196.8 million. </li>
<li>I-MAB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMAB#NASDAQ">IMAB</a>) stock increased by 29.1% to $0.86. The company's market cap stands at $69.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Ironwood Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) stock fell 30.0% to $0.66 during Monday's regular session. The market value of their outstanding shares is at $105.9 million. </li>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) stock declined by 22.36% to $0.24. The market value of their outstanding shares is at $19.9 million. </li>
<li>Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) shares declined by 21.84% to $5.07. The market value of their outstanding shares is at $275.5 million. </li>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) shares decreased by 17.92% to $0.38. The company's market cap stands at $4.2 million. </li>
<li>Bullfrog AI Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRG#NASDAQ">BFRG</a>) shares declined by 17.62% to $1.73. The company's market cap stands at $16.2 million. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) shares decreased by 17.58% to $0.95. The company's market cap stands at $1.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APDN

BFRG

IMAB

IRWD

MTSR

RSLS

STSS

THRD

WGRX

12 Health Care Stocks Moving In Monday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares rose 86.6% to $9.52 during Friday's regular session. The market value of their outstanding shares is at $15.6 million. </li>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSPR#NASDAQ">MSPR</a>) stock moved upwards by 85.15% to $2.37. The company's market cap stands at $5.0 million. </li>
<li>CeriBell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBLL#NASDAQ">CBLL</a>) shares rose 35.78% to $15.14. The company's market cap stands at $543.0 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares increased by 35.02% to $38.13. The company's market cap stands at $496.1 million. </li>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares moved upwards by 34.42% to $0.02. </li>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) shares rose 27.88% to $0.27. The company's market cap stands at $22.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) stock fell 53.3% to $2.31 during Friday's regular session. The company's market cap stands at $5.6 million. </li>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) stock declined by 44.04% to $0.24. The market value of their outstanding shares is at $6.1 million. </li>
<li>Wellgistics Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGRX#NASDAQ">WGRX</a>) shares declined by 29.45% to $2.76. The market value of their outstanding shares is at $143.2 million. </li>
<li>Organovo Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) stock fell 22.96% to $1.68. The market value of their outstanding shares is at $3.0 million. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) stock declined by 21.52% to $0.22. The company's market cap stands at $1.3 million. </li>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) shares declined by 15.96% to $0.48. The market value of their outstanding shares is at $5.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CBLL

LUCY

MSPR

ONVO

PRTG

YCBD

12 Health Care Stocks Moving In Friday's Intraday Session

Head and neck cancer patients treated with Multikine who had complete or partial tumor responses before surgery had improvements in overall survival, suggesting pre-surgical tumor response is a strong indicator of efficacy and leads to improved overall survival
A third-party head and neck cancer study published in "Cancer Cell" confirms the observation that pre-surgical tumor responses in head and neck cancer leads to improved survival
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcel-sci.com%2F&amp;esheet=54235406&amp;newsitemid=20250408565129&amp;lan=en-US&amp;anchor=CEL-SCI+Corporation&amp;index=1&amp;md5=8529d78500a48ee3a0fee230cd3462e9">CEL-SCI Corporation</a> (NYSE:<a href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) today announced that a study titled "Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies" by Li Housaiyin et. al., <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.sciencedirect.com%2Fscience%2Farticle%2Fpii%2FS1535610825000789%3Fvia%253Dihub&amp;esheet=54235406&amp;newsitemid=20250408565129&amp;lan=en-US&amp;anchor=Cancer+Cell&amp;index=2&amp;md5=a6109e5ec0a40224cd7c3f761761be2b">Cancer Cell</a> (2025) provides support for CEL-SCI's approach aimed at seeking early regulatory approval for Multikine&#x2A; (Leukocyte Interleukin, Injection) as a neoadjuvant in the treatment of newly diagnosed previously untreated locally advanced head and neck cancer based on early tumor responses.
The concept that tumor responses predict survival has been acknowledged for many cancer types and has led to accelerated approval of many cancer drugs. The study in Cancer Cell, which had 41 evaluable patients, gives further support that this is also true in the neoadjuvant pre-surgical immunotherapy treatment of head and neck cancer.

CEL-SCI Announces Study Published In 'Cancer Cell' Confirms Pre-Surgical Tumor Response In Head And Neck Cancer Patients Treated With Its  Multikine Improves Overall Survival, Supporting Early Regulatory Approval As A Neoadjuvant Treatment For Locally Advanced Head And Neck Cancer

Press Releases

CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients

New Study in the Scientific Journal "Cancer Cell" Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses

Small Cap

Opinion

With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz

CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market

CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results

CEL-SCI Announces Combination of Common Stock

CEL-SCI's Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia

Comments

CEL-SCI

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL